Pozahipotensyjne właściwości zofenoprilu – efekt grupy sulfhydrylowej Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2014
Słowa kluczowe:
ACE, zofenopril, miażdżyca
##plugins.themes.bootstrap3.article.main##
Abstrakt
Ponad 15 lat temu wykazano, że zofenopril, będący inhibitorem enzymu konwertującego angiotensynę (ACE) z podwójną grupą sulfhydrylową, jest skuteczny u pacjentów z nadciśnieniem tętniczym oraz po zawale serca. Celem tego artykułu przeglądowego jest podsumowanie informacji na temat zofenoprilu ze szczególnym uwzględnieniem właściwości fizyko-chemicznych oraz charakterystyki farmakokinetycznej i farmakodynamicznej, w tym jego wysokiej lipofilności, selektywnego hamowania ACE w mięśniu sercowym oraz usuwania wolnych rodników przez grupy sulfhydrylowe. Te właściwości odpowiedzialne są za kardioprotekcyjną aktywność zofenoprilu oraz jego wysoki potencjał w zapobieganiu chorobom układu sercowo-naczyniowego i ich leczeniu.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Postuła , M., & Kosior , D. (2014). Pozahipotensyjne właściwości zofenoprilu – efekt grupy sulfhydrylowej . Medycyna Faktów , 7(4(25), 81-84. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2343
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Lonn E.: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis. Curr. Atheroscler. Rep. 2002; 4: 363-372.
2. Dzau V.J.: Theodore Cooper lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047-1052.
3. Subissi A., Evangelista S., Giachetti A.: Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc. Drug Rev. 1999; 17: 115-133.
4. Cushman D.W., Wang F.L., Fung W.C. et al.: Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br. J. Clin. Pharmacol. 1989; 28(suppl. 2): S115-S130.
5. Ranadive S.A., Chen A.X., Serajuddin A.T.: Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharm. Res 1992; 9: 1480-1486.
6. Grover G.J., Sleph P.G., Dzwonczyk S. et al.: Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotection. J. Pharmacol. Exp. Ther. 1991; 257: 919-929.
7. Sargent C.A., Sleph P.G., Dzwonczyk S. et al.: Cardioprotection in ischemic rat hearts with the SH-containing angiotensin converting enzyme inhibitor zofenopril: possible involvement of the ATP-sensitive potassium channel. J. Pharmacol. Exp. Ther. 1993; 265: 609-618.
8. Frascarelli S., Ghelardoni S., Ronca-Testoni S. et al.: Cardioprotective effect of zofenopril in perfused rat heart subjected to ischemia and reperfusion. J. Cardiovasc. Pharmacol. 2004; 43: 294-249.
9. Westendorp B., Schoemaker R.G., Buikema H. et al.: Dietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated with attenuated hypertrophic response in rats with myocardial infarction. J. Renin Angiotensin Aldosterone Syst. 2004; 5: 27-32.
10. van Gilst W.H., de Graeff P.A., de Leeue M.J. et al.: Converting enzyme inhibitors and the role of the sulfhydryl group in the potentiation of exoand endogenous nitrovasodilatators. J. Cardiovasc. Pharmacol. 1991; 18: 429-436.
11. Napoli C., Loscalzo J.: New challenges for ACE-inhibitors in vascular diseases. Drug Design Rev. 2005; 2: 485-493.
12. Napoli C., Sica V., Pignalosa O. et al.: New trends in anti-atherosclerotic agents. Curr. Med. Chem. 2005; 12: 1755-1772.
13. Scribner A.W., Loscalzo J., Napoli C.: The effect of angiotensyn converting enzyme inhibition on endothelial function and oxidant stress. Eur. J. Pharmacol. 2003; 482: 95-99.
14. Napoli C., Sica V., de Nigris F. et al.: Sulfhydryl ACE inhibition induces a sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am. Heart J. 2004; 148: e5-e13.
15. Napoli C., Cicala C., D’Armiento F.P. et al.: Beneficial effects of ACE-inhibition with zofenopril on plaque formation and low-density lipoprotein oxidation in Watanabe heritable hyperlipidemic rabbits. Gen. Pharmacol. 1999; 33: 467-477.
16. Evangelista S., Manzini S.: Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J. Int. Med. Res. 2005; 33: 42-54.
17. Cominacini L., Pasini A., Garbin U. et al.: Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am. J. Hypertens. 2002; 15: 891-895.
18. Grobbee D.E., Bots M.L.: Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J. Intern. Med. 1994; 263: 567-573.
19. Mak I.T., Freedman A.M., Dickens B.F. et al.: Protective effects of sulfhydryl-containing angiotensin-converting enzyme inhibitors against free radical injury in endothelial cells. Biochem. Pharmacol. 1990; 40: 2169-2175.
20. Altunoluk B., Soylemez H., Oguz F. et al.: An angiotensin-converting enzyme inhibitor, zofenopril, prevents renal ischemia/reperfusion injury in rats. Ann. Clin. Lab. Sci. 2006; 36: 326-332.
21. Donnini S., Terzuoli E., Ziche M., Morbidelli L.: Sulfhydryl angiotensin-converting enzyme inhibitor promotes endothelial cell survival through nitric-oxide synthase, fibroblast growth factor-2, and telomerase cross-talk. J. Pharmacol. Exp. Ther. 2010; 332(3): 776-784.
22. Donnini S., Solito R., Giachetti A. et al.: Fibroblast growth factor-2 mediates angiotensin-converting enzyme inhibitor-induced angiogenesis in coronary endothelium. J. Pharmacol. Exp. Ther. 2006; 319(2): 515-522.
23. Riccioni G.: The Effect of Antihypertensive Drugs on Carotid Intima Media Thickness: An Up-to-Date Review. Curr. Med. Chem. 2009; 16: 988-996.
24. Napoli C., Bruzzese G., Ignarro L.J. et al.: Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima- media thickening and improves the nitric oxide⁄oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Am. Heart J. 2008; 156(6): 1154.
2. Dzau V.J.: Theodore Cooper lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047-1052.
3. Subissi A., Evangelista S., Giachetti A.: Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc. Drug Rev. 1999; 17: 115-133.
4. Cushman D.W., Wang F.L., Fung W.C. et al.: Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br. J. Clin. Pharmacol. 1989; 28(suppl. 2): S115-S130.
5. Ranadive S.A., Chen A.X., Serajuddin A.T.: Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharm. Res 1992; 9: 1480-1486.
6. Grover G.J., Sleph P.G., Dzwonczyk S. et al.: Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotection. J. Pharmacol. Exp. Ther. 1991; 257: 919-929.
7. Sargent C.A., Sleph P.G., Dzwonczyk S. et al.: Cardioprotection in ischemic rat hearts with the SH-containing angiotensin converting enzyme inhibitor zofenopril: possible involvement of the ATP-sensitive potassium channel. J. Pharmacol. Exp. Ther. 1993; 265: 609-618.
8. Frascarelli S., Ghelardoni S., Ronca-Testoni S. et al.: Cardioprotective effect of zofenopril in perfused rat heart subjected to ischemia and reperfusion. J. Cardiovasc. Pharmacol. 2004; 43: 294-249.
9. Westendorp B., Schoemaker R.G., Buikema H. et al.: Dietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated with attenuated hypertrophic response in rats with myocardial infarction. J. Renin Angiotensin Aldosterone Syst. 2004; 5: 27-32.
10. van Gilst W.H., de Graeff P.A., de Leeue M.J. et al.: Converting enzyme inhibitors and the role of the sulfhydryl group in the potentiation of exoand endogenous nitrovasodilatators. J. Cardiovasc. Pharmacol. 1991; 18: 429-436.
11. Napoli C., Loscalzo J.: New challenges for ACE-inhibitors in vascular diseases. Drug Design Rev. 2005; 2: 485-493.
12. Napoli C., Sica V., Pignalosa O. et al.: New trends in anti-atherosclerotic agents. Curr. Med. Chem. 2005; 12: 1755-1772.
13. Scribner A.W., Loscalzo J., Napoli C.: The effect of angiotensyn converting enzyme inhibition on endothelial function and oxidant stress. Eur. J. Pharmacol. 2003; 482: 95-99.
14. Napoli C., Sica V., de Nigris F. et al.: Sulfhydryl ACE inhibition induces a sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am. Heart J. 2004; 148: e5-e13.
15. Napoli C., Cicala C., D’Armiento F.P. et al.: Beneficial effects of ACE-inhibition with zofenopril on plaque formation and low-density lipoprotein oxidation in Watanabe heritable hyperlipidemic rabbits. Gen. Pharmacol. 1999; 33: 467-477.
16. Evangelista S., Manzini S.: Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J. Int. Med. Res. 2005; 33: 42-54.
17. Cominacini L., Pasini A., Garbin U. et al.: Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am. J. Hypertens. 2002; 15: 891-895.
18. Grobbee D.E., Bots M.L.: Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J. Intern. Med. 1994; 263: 567-573.
19. Mak I.T., Freedman A.M., Dickens B.F. et al.: Protective effects of sulfhydryl-containing angiotensin-converting enzyme inhibitors against free radical injury in endothelial cells. Biochem. Pharmacol. 1990; 40: 2169-2175.
20. Altunoluk B., Soylemez H., Oguz F. et al.: An angiotensin-converting enzyme inhibitor, zofenopril, prevents renal ischemia/reperfusion injury in rats. Ann. Clin. Lab. Sci. 2006; 36: 326-332.
21. Donnini S., Terzuoli E., Ziche M., Morbidelli L.: Sulfhydryl angiotensin-converting enzyme inhibitor promotes endothelial cell survival through nitric-oxide synthase, fibroblast growth factor-2, and telomerase cross-talk. J. Pharmacol. Exp. Ther. 2010; 332(3): 776-784.
22. Donnini S., Solito R., Giachetti A. et al.: Fibroblast growth factor-2 mediates angiotensin-converting enzyme inhibitor-induced angiogenesis in coronary endothelium. J. Pharmacol. Exp. Ther. 2006; 319(2): 515-522.
23. Riccioni G.: The Effect of Antihypertensive Drugs on Carotid Intima Media Thickness: An Up-to-Date Review. Curr. Med. Chem. 2009; 16: 988-996.
24. Napoli C., Bruzzese G., Ignarro L.J. et al.: Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima- media thickening and improves the nitric oxide⁄oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Am. Heart J. 2008; 156(6): 1154.